PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
AbClon holds pipeline momentum from the global Phase 3 progress of its Henlius-licensed HER2 antibody AC101 (HLX22) and the conditional-approval push for its in-house CAR-T candidate AT101, while revenue remains minimal and annual operating losses have widened for four consecutive years.
AC101 (HLX22) is in global Phase 3 trials for HER2-positive gastric cancer through Chinese partner Henlius, and its indication is expanding into breast cancer.
In-house CAR-T candidate AT101 (Nespecel) showed strong interim response rates in a domestic Phase 2 trial, and the company plans to file for conditional approval within the year.
2025 revenue increased year over year, but operating losses widened every year from 2022 through 2025, and the loss-making structure persists.
A 2025 capital raise sharply lowered the debt ratio, and the company was removed from KOSDAQ's administrative-issue designation in March 2026.
Earnings-based valuation metrics are not meaningful given continued losses, and the shares trade at a premium relative to net asset value.
AbClon is an antibody drug developer co-founded in 2010 by a group of Korean and Swedish scientists, operating around two core platforms: the proprietary antibody discovery platform NEST and the solid-tumor-targeting switchable CAR-T platform zCAR-T. Its core revenue model is technology licensing and royalties.
The HER2-targeting antibody AC101, discovered via NEST, had its China rights licensed to Shanghai Henlius Biotech in 2016 and its global rights in 2018.
AbClon transferred China rights to AC101 for about KRW 21.7 billion in 2016 and global rights for about KRW 42 billion in 2018, entitling AbClon to development milestones and sales royalties as AC101 progresses.
Of that royalty stream, 35% is shared with Sweden-based Alligator Bioscience, which participated in the early antibody discovery program.
The second pillar is the CAR-T business, centered on the CD19-targeting blood cancer candidate AT101 (Nespecel), which AbClon develops and runs clinical trials for domestically, alongside expansion into solid tumors with AT501 (ovarian cancer) and a bispecific prostate cancer candidate, AM109.
The company has also expanded next-generation cell therapy collaborations, including with GC Biopharma on an in-vivo CAR-T program based on an mRNA-LNP platform.
Revenue is derived not from product sales but from government R&D program funding, technology fees, and small licensing income, making it small in scale and lumpy across quarters.
Competitively, global CAR-T peers include Novartis's Kymriah and Gilead's Yescarta, plus domestic player Curocell's Lymkato, while in the HER2 antibody/ADC space, AC101's key differentiation is positioned around combination potential with existing standards of care such as Herceptin, Enhertu, and Perjeta.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.1B | -₩3.3B | −299.7% |
| 2025Q3 | ₩1.6B | -₩3.5B | −225.9% |
| 2025Q4 | ₩1.6B | -₩5B | −308.4% |
| 2026Q1 | ₩400M | -₩3.1B | −704.5% |
| 2026Q2 | ₩1.7B | -₩6.3B | −371.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩3.4B | -₩8.7B | -₩9.3B | −256.9% | −25.3% | 47.7% |
| 2023 | ₩2.9B | -₩11.6B | -₩12.9B | −404.8% | −47.4% | 66.9% |
| 2024 | ₩2.3B | -₩15.6B | -₩16.3B | −666.2% | −55.4% | 63.9% |
| 2025 | ₩4.7B | -₩17.6B | -₩17.9B | −374.1% | −29.6% | 17.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
AbClon's annual results show a clear pattern of widening losses. Revenue fell from KRW 3.406 billion in 2022 to KRW 2.877 billion in 2023 and KRW 2.340 billion in 2024, before rebounding to KRW 4.714 billion in 2025, though the absolute scale remains small.
Operating losses widened every year, from KRW -8.750 billion in 2022 to KRW -11.645 billion in 2023, KRW -15.589 billion in 2024, and KRW -17.636 billion in 2025.
The operating margin deteriorated from -256.9% in 2022 to -666.2% in 2024 before improving somewhat to -374.1% in 2025 on the back of higher revenue, though the loss structure remains severe.
Net loss attributable to owners similarly widened over the period, from KRW -9.254 billion to KRW -12.904 billion, KRW -16.302 billion, and KRW -17.907 billion.
On the balance sheet, owners' equity rose sharply to KRW 60.439 billion in 2025 from KRW 29.406 billion in 2024, a change attributable to external capital raising rather than earnings. The debt ratio dropped sharply from 63.9% in 2024 to 17.1% in 2025, easing the balance-sheet burden.
Operating cash flow deteriorated from KRW -7.492 billion in 2022 to KRW -14.394 billion in 2024 before remaining broadly negative at KRW -13.829 billion in 2025.
Quarterly, losses kept widening from KRW -3.333 billion on revenue of KRW 1.112 billion in 2025Q2, to KRW -3.538 billion/KRW 1.566 billion in Q3, and KRW -5.006 billion/KRW 1.623 billion in Q4; in 2026Q1 revenue plunged to KRW 0.434 billion yet the operating loss narrowed to KRW -3.059 billion.
However, in 2026Q2, revenue recovered to KRW 1.684 billion while the operating loss ballooned to KRW -6.255 billion, the largest in the observed window (2025Q3-2026Q2), indicating that rising R&D spending has become a direct drag on earnings.
Domestically, the CAR-T market has entered a commercialization phase in blood cancers. Novartis's Kymriah has been approved in Korea, opening up the domestic cell and gene therapy market, and Curocell's Lymkato, a Korean-developed CAR-T, has also entered the market, intensifying competition.
Kymriah's Phase 2 objective response rate (ORR) was 50% with a complete response (CR) rate of 32%, while Gilead's Yescarta recorded an ORR of 72% and CR of 51%. By contrast, AbClon's Nespecel showed a 94% ORR and 68% CR in interim Phase 2 data, higher than the incumbent products on an interim-data basis.
Industry watchers, however, note that whether the early positive signals hold up in the final data will be the key determinant of commercial success.
Solid tumor CAR-T remains at an early industry stage overall, with low response rates and cytokine release syndrome toxicity still hampering commercialization, making the validation of switchable, next-generation approaches like AbClon's zCAR-T and AT501 a key point to watch.
In the HER2 antibody/ADC market, incumbents such as Enhertu, Perjeta, and Herceptin are well established, and AC101 (HLX22) is attempting to differentiate through combination positioning based on its distinct epitope.
Partner Henlius has placed HLX22 within its new-launch innovative drug lineup and classified it as one of three top-tier blockbuster candidates, meaning that for AbClon, the partner's global execution speed and commercialization pace largely determine the pace of its own monetization.
For AT101 (Nespecel), the company has stated that it achieved a 94% objective response rate and 68% complete response rate in a domestic Phase 2 trial and plans to file for conditional approval with Korea's Ministry of Food and Drug Safety within the year.
For AC101 (HLX22), the global Phase 3 trial HLX22-GC-301, which dosed its first patient in November 2024, targets enrollment of 550 patients, and Henlius's CEO stated enrollment was more than 40% complete.
Indication expansion is also underway: in December 2025, China's National Medical Products Administration approved a Phase 2/3 trial plan for AC101 in HER2-positive breast cancer, covering first-line treatment and neoadjuvant therapy.
Henlius projects a possible overseas launch of HLX22 as early as 2028 and has set a revenue target of USD 10 billion, based solely on the value of the global gastric cancer Phase 3 and the HER2-low breast cancer Phase 2 trials.
Shinhan Investment Corp. stated in an August 4, 2026 report that a second-half turnaround could be expected via AC101 and AT101, and noted that Phase 2 results in China for AC101 combined with Enhertu in HER2-low/HR-positive breast cancer are due to be presented at ESMO in October, but did not issue a rating or target price.
The company's CEO also disclosed in a shareholder letter that toxicity data collection for AT501 is proceeding smoothly with plans to file an IND within the year, and that primate studies for AM105 have begun, with licensing and co-development negotiations with multiple companies underway for AM105 and AM109.
Because AbClon has recorded net losses every year, earnings-based valuation metrics cannot be meaningfully calculated, and the share price is largely shaped by expectations around future pipeline value and licensing outcomes.
Relative to net asset value, the shares trade at a sizable premium, a characteristic that can make valuation swing considerably around clinical events or licensing deals. No dividend is paid, consistent with the typical capital allocation approach of clinical-stage biotech companies that reinvest capital into R&D.
Given the still-small revenue base and continued losses shown in the historical results, the realization timing and probability of pipeline milestones and royalties function as the central valuation variable, more so than traditional earnings-multiple comparisons.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
The Henlius-led global Phase 3 trial for HLX22 in gastric cancer has enrolled more than 40% of patients and is expanding into breast cancer, broadening the pipeline's value base. Henlius's classification of HLX22 as a top-tier blockbuster candidate signals the partner's resource allocation priority. Upon clinical success and commercialization, AbClon is entitled to milestones and sales-linked royalties.
AT101 showed higher response rates than existing approved products in interim Phase 2 data, and the company has outlined a concrete regulatory path via a conditional approval filing planned within the year.
If successful, this could mark AbClon's first in-house product outside its pure licensing model, contributing to revenue diversification.
A 2025 capital raise sharply lowered the debt ratio, and the company was removed from KOSDAQ's administrative-issue designation in March 2026, resolving some balance-sheet-related uncertainty. This can be interpreted as securing funding capacity to sustain ongoing R&D activity.
Operating losses widened every year from 2022 through 2025, and operating cash flow has remained negative every year. The revenue base is still small, so the need for further capital raises to fund R&D persists. The 2026Q2 operating loss was the largest in the observed window.
Whether the interim data underpinning AT101's conditional approval basis will hold up in the final analysis has not been confirmed. Kymriah, Yescarta, and Curocell's Lymkato have already entered the domestic CAR-T market, intensifying competition.
The solid-tumor-focused zCAR-T and AT501 programs remain at an early stage with significant technical uncertainty.
The pace of HLX22's clinical progress and commercialization timing depends on Henlius's execution capability and overseas regulatory approval schedules.
Royalties range roughly from 3% to 5% depending on sales tiers, and 35% of that must be shared with Alligator Bioscience, meaning AbClon's actual take could be limited relative to overall drug sales. The 2028 commercialization target could also slip.
Persistent annual operating losses and negative operating cash flow create an ongoing need for additional capital. Future rights offerings or convertible bond issuances could dilute shareholder value. Even after the 2025 capital raise, continued funding management is necessary given the scale of R&D spending.
Approval timing and outcome for AT101's conditional approval filing depend on MFDS review results. AC101's global Phase 3 trial and breast cancer indication expansion trials are also subject to review timelines from regulators in multiple countries. The risk that interim data may not be sustained in final results cannot be ruled out.
Commercialization and monetization of AC101/HLX22 depend on the strategy and execution speed of Henlius (and parent company Fosun Pharma).
Given the royalty-sharing structure, AbClon's take is limited, and any shift in the partner's priorities or clinical delays could correspondingly delay the timing of AbClon's expected revenue realization.
China Phase 2 results for AC101 combined with Enhertu in first-line HER2-low/HR-positive breast cancer are scheduled to be presented at ESMO. The efficacy data from this combination could shape the value of AC101's indication expansion.
Watch whether and when AbClon actually files for conditional approval of AT101 with the MFDS. It is also worth monitoring whether final Phase 2 data maintains the level shown in interim results.
Confirm whether the company files an investigational new drug (IND) application for AT501 (solid tumor CAR-T), as stated by management. A filing would represent concrete progress in pipeline expansion.
The 2026Q3 earnings disclosure will allow reassessment of revenue and operating-loss trends, as well as the pace of R&D expenditure.
Monitor whether ongoing licensing and co-development negotiations for AM105 and AM109 with multiple companies translate into actual signed agreements.
AbClon holds two strands of pipeline momentum: the global Phase 3 progress and breast cancer indication expansion of AC101 (HLX22) through Henlius, and the domestic conditional-approval push for its in-house CAR-T candidate AT101.
At the same time, its revenue base remains small, operating losses have widened for four consecutive years, and operating cash flow has stayed negative, sustaining reliance on external capital.
The 2025 capital raise lowered the debt ratio and lifted the administrative-issue designation, but this reflects external funding inflows rather than earnings improvement.
Whether AT101's interim data holds up in final results, and whether HLX22's global Phase 3 and breast cancer expansion trials proceed on schedule, are the key variables for future valuation.
It is also worth noting that, given the royalty-sharing structure, AbClon's actual take may be limited even if commercialization succeeds.
Investors should continue to monitor verifiable upcoming events—the ESMO presentation, the conditional approval filing, and quarterly earnings disclosures—to track the balance between pipeline progress and financial burden.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.